Patient characteristics
| Characteristic . | All patients . | Young . | Middle . | Old . |
|---|---|---|---|---|
| No. | 525 | 175 | 175 | 175 |
| Age at diagnosis, y | 46.6 (15.2-77.2) | 31.1* (15.2-39.4) | 46.6* (39.4-53.6) | 59.4* (53.6-77.2) |
| White blood cell count (× 109/L) | 26 (0.3-510) | 25 (1-44) | 34 (0.3-278) | 27 (1-510) |
| Bone marrow blasts (%) | 65 (1-99) | 69 (4-98) | 66 (1-99) | 62 (1-99) |
| Platelets (× 109/L) | 56 (3-998) | 44* (3-339) | 55* (5-998) | 66* (8-722) |
| Cytogenetics | ||||
| Favorable | 89 (17%) | 50* (29%) | 27* (15%) | 12* (7%) |
| t(8;21) | 34 | 19* | 13* | 2* |
| t(15;17) | 20 | 13* | 5* | 2* |
| inv16 | 35 | 18* | 9* | 8* |
| Intermediate | 331 (63%) | 93 (53%) | 119 (68%) | 119 (68%) |
| Normal karyotype | 218 | 57 | 82 | 79 |
| +8 | 25 | 12 | 7 | 6 |
| −9q | 7 | 2 | 1 | 4 |
| Other | 81 | 22 | 29 | 30 |
| Unfavorable | 85 (16%) | 26 (15%) | 22 (13%) | 37 (21%) |
| 11q23 | 11 | 4 | 5 | 2 |
| Complex | 20 | 4 | 4 | 12 |
| −5(q)/−7(q) | 42 | 15 | 6 | 21 |
| abn(3q) | 2 | 0 | 2 | 0 |
| t(6;9) | 6 | 1 | 4 | 1 |
| t(9;22) | 2 | 2 | 0 | 0 |
| Other | 2 | 0 | 1 | 1 |
| Not available | 20 (4%) | 6 (3%) | 7 (4%) | 7 (4%) |
| NPM1 mutation without FLT3-ITD | 77 (15%) | 13* | 35* | 29* |
| NPM1 mutation with FLT3-ITD | 82 (15%) | 20 | 29 | 33 |
| NPM1 wild-type without FLT3-ITD | 305 (58%) | 120 | 90 | 95 |
| NPM1 wild-type with FLT3-ITD | 61 (12%) | 22 | 21 | 18 |
| No SCT | 312 | 81* | 104* | 127* |
| Allogeneic SCT | 140† | 65* | 52*‡ | 23*§ |
| Autologous SCT | 68 | 29 | 19 | 20 |
| Not available | 5 | 0 | 0 | 5 |
| Cycles to CR, n (%) | ||||
| 1 | 297 (57) | 88 (50.3) | 109 (62.3) | 100 (57.1) |
| 2 | 111 (21) | 53* (30.3) | 33* (18.9) | 25* (14.3) |
| 3 | 8 (2) | 2 (1.1) | 4 (2.3) | 2 (1.1) |
| More than 3 | 5 (1) | 2 (1.1) | 2 (1.1) | 1 (0.6) |
| No CR | 104 (20) | 30 (17.2) | 27 (15.4) | 47 (26.9) |
| Relapse, n (%) | 202 (39) | 70 (40) | 70 (40.0) | 62 (35.0) |
| Dead/alive | 316/209 | 92/83 | 111/64 | 113/62 |
| Characteristic . | All patients . | Young . | Middle . | Old . |
|---|---|---|---|---|
| No. | 525 | 175 | 175 | 175 |
| Age at diagnosis, y | 46.6 (15.2-77.2) | 31.1* (15.2-39.4) | 46.6* (39.4-53.6) | 59.4* (53.6-77.2) |
| White blood cell count (× 109/L) | 26 (0.3-510) | 25 (1-44) | 34 (0.3-278) | 27 (1-510) |
| Bone marrow blasts (%) | 65 (1-99) | 69 (4-98) | 66 (1-99) | 62 (1-99) |
| Platelets (× 109/L) | 56 (3-998) | 44* (3-339) | 55* (5-998) | 66* (8-722) |
| Cytogenetics | ||||
| Favorable | 89 (17%) | 50* (29%) | 27* (15%) | 12* (7%) |
| t(8;21) | 34 | 19* | 13* | 2* |
| t(15;17) | 20 | 13* | 5* | 2* |
| inv16 | 35 | 18* | 9* | 8* |
| Intermediate | 331 (63%) | 93 (53%) | 119 (68%) | 119 (68%) |
| Normal karyotype | 218 | 57 | 82 | 79 |
| +8 | 25 | 12 | 7 | 6 |
| −9q | 7 | 2 | 1 | 4 |
| Other | 81 | 22 | 29 | 30 |
| Unfavorable | 85 (16%) | 26 (15%) | 22 (13%) | 37 (21%) |
| 11q23 | 11 | 4 | 5 | 2 |
| Complex | 20 | 4 | 4 | 12 |
| −5(q)/−7(q) | 42 | 15 | 6 | 21 |
| abn(3q) | 2 | 0 | 2 | 0 |
| t(6;9) | 6 | 1 | 4 | 1 |
| t(9;22) | 2 | 2 | 0 | 0 |
| Other | 2 | 0 | 1 | 1 |
| Not available | 20 (4%) | 6 (3%) | 7 (4%) | 7 (4%) |
| NPM1 mutation without FLT3-ITD | 77 (15%) | 13* | 35* | 29* |
| NPM1 mutation with FLT3-ITD | 82 (15%) | 20 | 29 | 33 |
| NPM1 wild-type without FLT3-ITD | 305 (58%) | 120 | 90 | 95 |
| NPM1 wild-type with FLT3-ITD | 61 (12%) | 22 | 21 | 18 |
| No SCT | 312 | 81* | 104* | 127* |
| Allogeneic SCT | 140† | 65* | 52*‡ | 23*§ |
| Autologous SCT | 68 | 29 | 19 | 20 |
| Not available | 5 | 0 | 0 | 5 |
| Cycles to CR, n (%) | ||||
| 1 | 297 (57) | 88 (50.3) | 109 (62.3) | 100 (57.1) |
| 2 | 111 (21) | 53* (30.3) | 33* (18.9) | 25* (14.3) |
| 3 | 8 (2) | 2 (1.1) | 4 (2.3) | 2 (1.1) |
| More than 3 | 5 (1) | 2 (1.1) | 2 (1.1) | 1 (0.6) |
| No CR | 104 (20) | 30 (17.2) | 27 (15.4) | 47 (26.9) |
| Relapse, n (%) | 202 (39) | 70 (40) | 70 (40.0) | 62 (35.0) |
| Dead/alive | 316/209 | 92/83 | 111/64 | 113/62 |
Young, middle, and old indicate the youngest, middle, and oldest third of the patients, respectively. Characteristics—age, WBC, percentage bone marrow blasts and platelets—are given as median (range).
Significant difference, younger versus middle versus older patients (P < .01).
A total of 12 of 140 patients with an allogeneic HCT after nonmyeloablative conditioning.
A total of 1 of 52 patients with an allogeneic HCT after nonmyeloablative conditioning.
A total of 11 of 23 patients with an allogeneic HCT after nonmyeloablative conditioning.